These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 6236870)

  • 21. Endocrine factors in the treatment of prostatic cancer.
    Pierrepoint CG; Turkes AO; Walker KJ; Harper ME; Wilson DW; Peeling WB; Griffiths K
    Prog Clin Biol Res; 1985; 185A():51-72. PubMed ID: 3162177
    [No Abstract]   [Full Text] [Related]  

  • 22. Effective long-term suppression of pituitary-gonadal axis in prostatic cancer by Zoladex (ICI 118,630).
    Murphy GP; Greco J; Huben R
    Urology; 1987 Nov; 30(5):482-3. PubMed ID: 2960064
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacology of the luteinising hormone-releasing hormone (LHRH) analogue, Zoladex.
    Furr BJ
    Horm Res; 1989; 32 Suppl 1():86-92. PubMed ID: 2533160
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of previous endocrine therapy on responses to a single dose of an LHRH analogue.
    Allen JM; Williams G; O'Shea JP; Smith C; Yeo T; Kerle D; Bloom SR
    Urol Res; 1984; 12(5):249-51. PubMed ID: 6240150
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment of advanced cancer of the prostate with an analog of LHRH, buserelin].
    Wenderoth UK; Jacobi GH
    Ann Urol (Paris); 1986; 20(2):95-7. PubMed ID: 3087269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of continuous luteinizing hormone-releasing hormone agonist treatment on steroidogenic enzymes in the human testis.
    Petersson F; Hammar M; Mathson K; Hjertberg H; Varenhorst E
    Scand J Urol Nephrol; 1987; 21(4):267-71. PubMed ID: 2965409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Results of a Dutch Phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer.
    Debruyne FM; Karthaus HF; Schröder FH; de Voogt HJ; de Jong FH; Klijn JG
    Prog Clin Biol Res; 1985; 185A():251-70. PubMed ID: 3929265
    [No Abstract]   [Full Text] [Related]  

  • 28. The treatment of metastatic prostatic cancer with the slow release LH-RH analogue Zoladex ICI 118630.
    Beacock CJ; Buck AC; Zwinck R; Peeling WB; Rees RW; Turkes A; Walker K; Griffiths K
    Br J Urol; 1987 May; 59(5):436-42. PubMed ID: 2954605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Failure of long term luteinising hormone releasing hormone to suppress testosterone.
    Faure N
    Br Med J (Clin Res Ed); 1984 Nov; 289(6455):1380-1. PubMed ID: 6437557
    [No Abstract]   [Full Text] [Related]  

  • 30. Testosterone and gonadotrophin profiles in patients on daily or monthly LHRH analogue ICI 118630 (Zoladex) compared with orchiectomy.
    Grant JB; Ahmed SR; Shalet SM; Costello CB; Howell A; Blacklock NJ
    Br J Urol; 1986 Oct; 58(5):539-44. PubMed ID: 2946356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical effect of slow release (depot) formulation of the LH-RH analogue ICI 118630 (Zoladex) in patients with prostatic carcinoma].
    Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Sonoda T
    Hinyokika Kiyo; 1987 Jan; 33(1):141-50. PubMed ID: 2953179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. LHRH analogues in combination with an anti-androgen in the treatment of advanced disease.
    Denis L
    Horm Res; 1989; 32 Suppl 1():66-7; discussion 68. PubMed ID: 2533158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review of the endocrine actions of luteinising hormone-releasing hormone analogues in premenopausal women with breast cancer.
    Nicholson RI; Walker KJ; Walker RF; Read GF; Turkes A; Robertson JF; Blamey RW
    Horm Res; 1989; 32 Suppl 1():198-201. PubMed ID: 2533149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Chemical castration using a depot LHRH-agonist as a palliative therapy concept in prostatic carcinoma--clinical, endocrinological and experimental studies].
    Kuber W; Treu T; Kratzik C; Girsch E; Zeillinger R; Spona J
    Wien Klin Wochenschr; 1990 Nov; 102(21):640-7. PubMed ID: 2148044
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions.
    Chrisp P; Goa KL
    Drugs; 1991 Feb; 41(2):254-88. PubMed ID: 1709853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of advanced carcinoma of the prostate with a depot luteinizing hormone-releasing hormone analogue (ICI-118630).
    Van Cangh PJ; Opsomer RJ
    J Urol; 1987 Jan; 137(1):61-4. PubMed ID: 2948026
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostatic cancer: treatment with long-acting LHRH analogue.
    Williams G; Allen JM; O'Shea JP; Mashiter K; Doble A; Bloom SR
    Br J Urol; 1983 Dec; 55(6):743-6. PubMed ID: 6228283
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of advanced prostatic cancer with LHRH-analogues. Prevention of "flare-up" phenomenon.
    Bouffioux C; Denis L; Mahler C; de Leval J
    Prog Clin Biol Res; 1987; 243A():255-60. PubMed ID: 2958857
    [No Abstract]   [Full Text] [Related]  

  • 39. A multicenter trial comparing the luteinizing hormone releasing hormone analog Zoladex, with Zoladex plus flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group.
    Lunglmayr G
    Eur Urol; 1990; 18 Suppl 3():28-9. PubMed ID: 2151273
    [No Abstract]   [Full Text] [Related]  

  • 40. Long term therapy with a depot LHRH analogue (Zoladex) in patients with advanced prostatic cancer.
    Denis L; Keuppens F; Mahler C; Debruyne FM; Weil EH; Lunglmayr G; Newling D; Robinson MR; Richards B; Smith PH
    Prog Clin Biol Res; 1987; 243A():221-7. PubMed ID: 2958852
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.